Epinephrine Injection (Auto-Injector)

Introduction Overview

Generic Name

epinephrine injection (auto-injector)

Brand Name

Auvi-Q

Dosage Form

Disposable single-use auto-injector containing epinephrine injection for intramuscular or subcutaneous administration

Drug Class

Adrenergic bronchodilators, Catecholamines, Vasopressors

Pharmacokinetics

Absorption

Following intramuscular or subcutaneous injection via the Auvi-Q auto-injector, epinephrine is rapidly absorbed into systemic circulation. Studies demonstrate peak plasma concentrations typically occur within minutes (generally 5 to 10 minutes). Absorption rate can be influenced by injection site vascularity, with the intramuscular route in the outer thigh showing more consistent and rapid absorption compared to subcutaneous routes. During anaphylaxis, physiological alterations such as vasodilation may also impact absorption kinetics, but epinephrine’s rapid onset remains critical for therapeutic efficacy.

Distribution

Once absorbed, epinephrine distributes widely throughout the body, crossing capillary membranes and reaching target tissues including the heart, lungs, blood vessels, and central nervous system. The volume of distribution is relatively low as epinephrine is a polar catecholamine, approximately 0.3 to 0.5 L/kg. Epinephrine does not significantly bind to plasma proteins, and its distribution reflects rapid equilibration between the vascular compartment and interstitial spaces.

Metabolism

Epinephrine is extensively metabolized by enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO), predominantly in the liver and other tissues such as kidneys and lungs. It undergoes O-methylation and oxidative deamination producing inactive metabolites like metanephrine and vanillylmandelic acid (VMA) which are excreted renally. The metabolism is rapid, resulting in a plasma half-life of approximately 2 to 3 minutes. This rapid metabolism necessitates prompt and sometimes repeat dosing during anaphylaxis treatment.

Elimination

Metabolites of epinephrine are primarily eliminated by renal excretion. Less than 1% of administered epinephrine is excreted unchanged in urine. The short plasma half-life and efficient metabolism mean epinephrine effects are transient; hence, patients treated with Auvi-Q require immediate medical evaluation after administration to monitor for re-emergence of symptoms or need for additional doses.

Dosage Forms

Adults

For adults and adolescents weighing 30 kg (66 lbs) or more, the recommended dose is 0.3 mg of epinephrine injected intramuscularly (IM) into the mid-outer thigh using the Auvi-Q auto-injector. The dose may be repeated every 5 to 15 minutes as necessary in severe anaphylaxis, under medical supervision.

Adolescents

Adolescents (weighing 30 kg or more) use the adult dose of 0.3 mg IM. For children weighing between 16.5 kg (36 lbs) and 30 kg (66 lbs), the recommended dose is 0.15 mg IM. Children under 16.5 kg are generally not recommended to use Auvi-Q and should have alternative dosing options.

Special Populations

Special considerations exist for pediatric patients below 16.5 kg who may require alternative administration devices or dosing. Pregnant and breastfeeding women may use Auvi-Q in emergencies but must seek immediate medical care after use. Elderly patients may exhibit increased sensitivity to epinephrine’s cardiovascular effects. Patients with comorbidities such as cardiovascular disease, hypertension, hyperthyroidism, diabetes, or Parkinson's disease require cautious use and close monitoring.

Mechanism Of Action

Epinephrine acts as a non-selective adrenergic agonist, stimulating alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors throughout the body. Activation of alpha-1 receptors induces vasoconstriction in vascular smooth muscle, leading to increased peripheral vascular resistance and elevation of blood pressure, which is essential in counteracting the profound hypotension observed in anaphylaxis.

Beta-1 receptor stimulation leads to enhanced cardiac contractility (positive inotropic effect) and heart rate (positive chronotropic effect), improving cardiac output during circulatory shock. Beta-2 receptor activation causes relaxation of bronchial smooth muscle, dilating the airways and alleviating respiratory distress such as wheezing and bronchospasm.

At the cellular level, epinephrine binding to these G-protein coupled receptors activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP), which mediates downstream pathways leading to smooth muscle relaxation in the lungs and contraction in vascular smooth muscle. Furthermore, epinephrine stabilizes mast cells and basophils, reducing the release of histamine and other mediators that exacerbate anaphylaxis.

Comparatively, epinephrine's balanced alpha and beta receptor activity distinguishes it from other adrenergic agonists, making it the drug of choice for rapid reversal of life-threatening allergic reactions. Clinical studies support epinephrine’s efficacy in reducing anaphylaxis morbidity and mortality when administered promptly via auto-injectors like Auvi-Q.

Pharmacological Actions

Vasoconstriction via alpha-1 adrenergic receptor activation, raising blood pressure
Bronchodilation via beta-2 adrenergic receptor stimulation, relieving airway constriction
Increased cardiac output through beta-1 adrenergic receptor effects, enhancing heart rate and contractility
Inhibition of mediator release from mast cells and basophils, reducing allergy symptom progression
Reduction of mucosal edema in airways and nasopharynx
Stimulation of glycogenolysis increasing blood glucose levels transiently
Increased lipolysis mediated through beta-adrenergic receptors
Central nervous system effects including increased alertness

Therapeutic Clinical Uses

Emergency treatment of severe allergic reactions (anaphylaxis) due to insect stings or bites, foods, drugs, and other allergens
Treatment of exercise-induced anaphylaxis
Used as an emergency self-injectable medication in individuals with a history of life-threatening allergic reactions
Adjunct treatment for hypotension and shock in medical emergencies
Temporary relief of acute bronchospasm in asthma patients refractory to other bronchodilators (off-label)
Management of croup and airway obstruction in pediatric emergencies (off-label)
Counteracting severe hypersensitivity reactions during anesthesia or diagnostic procedures
First-line therapy for cardiac arrest during advanced life support (not specifically via Auvi-Q)

Side Or Adverse Effects

Tachycardia and palpitations due to beta-1 adrenergic stimulation
Hypertension and possible vascular headache from alpha-1 induced vasoconstriction
Tremors and nervousness related to beta-2 receptor activation
Pallor and sweating secondary to vasoconstriction and sympathetic stimulation
Dizziness and weakness possibly from transient blood pressure changes
Nausea and vomiting during systemic adrenergic effects
Localized pain, swelling, or redness at the injection site
Risk of accidental injection causing localized ischemia, particularly in fingers or toes
Rare hypersensitivity to the drug or device components
Potential for cardiac arrhythmias in susceptible individuals
Increased risk of myocardial ischemia in patients with coronary artery disease

Precautions

Always seek emergency medical attention immediately after Auvi-Q use due to potential re-emergence of symptoms
Ensure proper training on auto-injector use to avoid administration errors
Patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, or Parkinson’s disease require careful monitoring
Avoid injection into veins or buttocks as efficacy decreases and injury risk increases
Do not reuse Auvi-Q auto-injectors; single-use only
Monitor for signs of overdose or toxicity such as severe headache, chest pain, and arrhythmias
Store at room temperature protected from moisture, heat, and light—do not refrigerate or freeze
Check expiration dates regularly and do not use if solution is discolored or contains particles
Inform healthcare providers of all concurrent medications to avoid interactions
Exercise caution in pregnant or breastfeeding patients; use only if benefits outweigh risks

Warnings

Seek immediate emergency care after any use of Auvi-Q; further observation and treatment are crucial
Device contains a needle with an automatic retraction system to prevent needle-stick injuries, but accidental injection remains a risk
Use only as directed; do not attempt to reinsert the auto-injector after use
Improper administration may lead to serious tissue injury, including gangrene if injected into digits
Use cautiously in elderly patients due to increased cardiovascular risk
Excessive dosing/inadvertent overdose can cause severe cardiovascular and CNS effects, potentially fatal
Use may exacerbate pre-existing cardiac arrhythmias or ischemic heart disease
Caution in patients with history of hypertension or tachyarrhythmias
Avoid use if medication solution appears cloudy, discolored, or contains particulate matter
Concomitant use with monoamine oxidase inhibitors (MAOIs) may potentiate effects and toxicity

Contraindications

No absolute contraindications in life-threatening anaphylaxis emergencies; benefits generally outweigh risks
Known hypersensitivity to epinephrine or any component of the Auvi-Q formulation
Do not administer into digits, toes, ears, nose, or genitalia due to risk of ischemia
Use with extreme caution or contraindicated in patients with severe cardiovascular disorders unless no alternatives

Drug Interactions

Additive hypertensive and cardiac effects when combined with other sympathomimetic drugs
Potential diminished effect with beta-blockers due to receptor antagonism
MAO inhibitors and tricyclic antidepressants may potentiate epinephrine response, increasing risk of hypertension and arrhythmias
Increased risk of ergot alkaloid toxicity when given concurrently due to vasoconstriction
Drugs affecting metabolism of catecholamines may alter epinephrine pharmacodynamics
Additive effects with other adrenergic bronchodilators
Caution with anesthetics that sensitize myocardium to catecholamines, increasing arrhythmia risk
Antihistamines and corticosteroids do not block epinephrine but may affect overall anaphylaxis management
Alcohol and CNS depressants may mask symptom severity; monitor closely
Interactions with thyroid medications may potentiate adrenergic effects

Preparations Of The Drug

Auvi-Q auto-injector, single-use, disposable device containing epinephrine injection
Dosage strengths: 0.3 mg epinephrine for patients weighing 30 kg or more (usually adults and adolescents)
0.15 mg epinephrine auto-injector for pediatric patients weighing 16.5–30 kg
Each device includes an electronic voice guidance system providing step-by-step injection instructions
Available with a trainer pen device containing no needle or medication for practice use
Packaging available in single units or 2-packs
Supplied as a prefilled sterile solution of epinephrine hydrochloride at 1 mg/mL concentration
Devices designed for intramuscular or subcutaneous use in the mid-outer thigh
Storage instructions: room temperature, protected from light and moisture, non-refrigerated
Prescribed for emergency self-administration in community and clinical settings